ecteinascidin 743 has been researched along with Disease Models, Animal in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W; Deng, W; Hao, Q; Huang, Z; Li, J; Li, Q; Liu, D; Liu, Z; Su, R; Vadgama, J; Wang, K; Wang, P; Wu, K; Wu, Y | 1 |
| Bouvet, M; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G | 1 |
| Bongiovanni, A; Brandolini, F; Calpona, S; Casadei, R; Cavaliere, D; Cocchi, C; De Vita, A; Debonis, SA; Di Menna, G; Ercolani, G; Fabbri, F; Farnedi, A; Fausti, V; Gurrieri, L; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Pieri, F; Recine, F; Riva, N; Spadazzi, C; Vanni, S | 1 |
| Chiba, K; Horiuchi, K; Inoue, M; Ishizaka, T; Matsuhashi, Y; Rikitake, H; Susa, M; Taguchi, E | 1 |
| Ballabio, S; Barisella, M; Bello, E; Callari, M; Casali, PG; Craparotta, I; D'Incalci, M; Fabbroni, C; Frapolli, R; Mannarino, L; Marchini, S; Meroni, M; Panini, N; Sanfilippo, R | 1 |
| Daignault, S; Hofbauer, LC; Jones, JD; Koh, AJ; McCauley, LK; Paige, D; Roca, H; Shiozawa, Y; Sinder, BP; Soki, FN; Thiele, S | 1 |
| Boguslawski, EA; Bowman, MJ; Chasse, MH; Gedminas, JM; Grohar, PJ; Harlow, ML; Kitchen-Goosen, SM; Lessnick, SL; Madaj, ZB; Peck, AS; Rothbart, SB; Sorensen, KM; Taslim, C | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| D'Incalci, M; Grohar, PJ; Helman, LJ; Mendoza, A; Pommier, Y; Segars, LE; Yeung, C | 1 |
| Guo, Z; Li, J; Meng, F; Wang, H; Zhang, S | 1 |
| Charytonowicz, E; Coakley, K; Cordon-Cardo, C; Matushansky, I; Remotti, F; Taub, RN; Telis, L; Terry, M | 1 |
11 other study(ies) available for ecteinascidin 743 and Disease Models, Animal
| Article | Year |
|---|---|
A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Glucose; Glycolysis; Humans; Hypoglycemic Agents; Lactic Acid; Metformin; Mice; Monocarboxylic Acid Transporters; Muscle Proteins; Prognosis; Trabectedin | 2022 |
Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Fluorouracil; Humans; Mice; Mice, Nude; Oxaliplatin; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models.
Topics: Animals; Antineoplastic Agents, Alkylating; Disease Models, Animal; Extracellular Matrix; Humans; Sarcoma; Trabectedin; Zebrafish | 2021 |
Trabectedin suppresses osteosarcoma pulmonary metastasis in a mouse tumor xenograft model.
Topics: Adolescent; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Heterografts; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Osteosarcoma; Trabectedin | 2022 |
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
Topics: Adult; Animals; Disease Models, Animal; Humans; Liposarcoma, Myxoid; Mice; Trabectedin | 2021 |
Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Immunohistochemistry; Macrophage Activation; Macrophages; Male; Mice; Phagocytosis; Phenotype; Prostatic Neoplasms; Trabectedin; Xenograft Model Antitumor Assays | 2019 |
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chromatin; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Mice; Oncogene Proteins, Fusion; Protein Binding; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; Sarcoma, Ewing; Trabectedin; Transcription Factors; Xenograft Model Antitumor Assays | 2019 |
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Topics: Adolescent; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Irinotecan; Male; Mice, Nude; Osteosarcoma; Topoisomerase I Inhibitors; Trabectedin | 2019 |
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dioxoles; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Irinotecan; Mice; Oncogene Proteins, Fusion; Phenotype; Proto-Oncogene Protein c-fli-1; RecQ Helicases; RNA Interference; RNA-Binding Protein EWS; RNA, Small Interfering; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Werner Syndrome Helicase; Xenograft Model Antitumor Assays | 2014 |
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Topics: Animals; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Dioxoles; Disease Models, Animal; Drug Synergism; Female; Immunization; Immunosuppression Therapy; Interferon-gamma; Mice, Inbred C57BL; Ovarian Neoplasms; Peritoneal Lavage; Programmed Cell Death 1 Receptor; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2015 |
PPARĪ³ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Cell Differentiation; Dioxoles; Disease Models, Animal; Drug Synergism; Female; Humans; Liposarcoma, Myxoid; Male; Mice; Mice, Transgenic; Middle Aged; Neoplasm Transplantation; PPAR gamma; Tetrahydroisoquinolines; Trabectedin | 2012 |